Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methylprednisolone acetate
Drug ID BADD_D01434
Description Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone].[A188811] It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957.[L10785] In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression.[A192813] The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials.[L12666]
Indications and Usage Adjunctive therapy for short-term administration in rheumatoid arthritis.
Marketing Status Prescription; Discontinued
ATC Code D07AA01; D10AA02; H02AB04
DrugBank ID DB00959
KEGG ID D00979
MeSH ID D000077555
PubChem ID 5877
TTD Drug ID Not Available
NDC Product Code 50090-0436; 0009-0306; 0009-3475; 38779-0144; 50090-4802; 70518-2894; 50090-0312; 46439-8767; 0009-0274; 60219-1573; 25021-821; 0009-0280; 0009-3073; 50090-0556; 70518-2914; 63187-474; 50090-5894; 16714-089; 0703-0045; 25021-820; 0703-0043; 76420-081; 0703-0063; 70518-2965; 51927-0000; 16714-472; 51552-0958; 70518-2459; 70518-3071; 70121-1552; 50090-1823; 16714-473; 49452-4688; 0703-0051; 70121-1573; 51662-1429; 0009-0026; 76420-260; 0703-0031; 10695-041; 76420-262; 16714-090; 22552-0023; 63275-9942; 68788-8082; 60219-1574; 70121-1574; 70518-2915; 50090-2098; 65089-0016; 16714-088; 82298-117; 52128-148
Synonyms Methylprednisolone Acetate | Methylprednisolone-21-acetate | Methylprednisolone 21 acetate | Acetyl-Methylprednisolone | Acetyl Methylprednisolone | Depo-Medrone | Depo Medrone | Depo-Medrol | Depo Medrol | Methylprednisolone Acetate, (11beta,16beta)-isomer | Methylprednisolone Acetate, (11beta,16alpha)-isomer
Chemical Information
Molecular Formula C24H32O6
CAS Registry Number 53-36-1
SMILES CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Increased appetite08.01.09.027; 14.03.01.003--Not Available
Increased insulin requirement14.06.01.006; 05.06.01.006--Not Available
Infection11.01.08.002--Not Available
Infection susceptibility increased11.01.08.004; 10.02.01.046--Not Available
Injection site abscess12.07.03.021; 11.01.08.023; 08.02.03.021--Not Available
Injection site infection12.07.03.008; 11.01.08.005; 08.02.03.019--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Insomnia19.02.01.002; 17.15.03.002--
Intestinal perforation07.04.06.002--Not Available
Intracranial pressure increased17.07.02.002--Not Available
Intraocular pressure increased13.07.04.002--Not Available
Irritability19.04.02.013; 08.01.03.011--
Large intestine perforation07.04.06.005; 12.02.03.005--
Leukocytosis01.02.01.002--
Leukoderma23.05.02.001--Not Available
Malaise08.01.01.003--
Mania19.16.02.002--
Meningitis17.06.03.001; 11.01.03.001--
Menstruation irregular05.05.01.008; 21.01.01.005--
Metabolic acidosis14.01.01.003--Not Available
Monoplegia17.01.04.003--Not Available
Mood swings19.04.03.001--Not Available
Muscle atrophy17.05.03.004; 15.05.03.003--Not Available
Muscle disorder15.05.03.014--Not Available
Muscular weakness17.05.03.005; 15.05.06.001--
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Myocardial rupture12.01.11.002; 02.04.02.002--Not Available
Myopathy15.05.05.001--Not Available
Nausea07.01.07.001--
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 8 Pages